Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 11/27/2006 First Published: 2/21/2003


1.		Phase III Randomized Study of Imatinib Mesylate Alone or With Interferon alfa or Low-Dose Cytarabine Versus Interferon alfa Standard Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Any age				Other				III-MK-CML-IV EU-20248, NCT00055874


2.		Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				IRB 13362B NCT00117572


3.		A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				UCIRB #14733B GV-001.011 (TNF-CORE), NCT00496535


4.		A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				12652A NCT00203905

First Published: 7/14/2006


5.		Phase II Study of Imatinib Mesylate and Hydroxyurea in Patients With Recurrent or Progressive Meningioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				NCI, Pharmaceutical / Industry				DUMC-7082-05-4R0 NOVARTIS-DUMC-7082-05-4R0, NCT00354913


6.		Fluorouracil, Hydroxyurea, Cetuximab and Twice-Daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				GCO 06-1155 NCT00462735


7.		Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				14401A NCT00468169


8.		Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent MG

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				Other				00000393 NCT00613054


9.		Combination of Hydroxyurea and Verapamil for Refractory Meningiomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				Other				HCI # 25089 NCT00706810

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute